Oppenheimer Holdings Stock News

Starbucks lagged the broader market in 2021 and could struggle to rise in 2022, according to RBC and Oppenheimer.

SPX Co. (NYSE:SPXC) Equities research analysts at Oppenheimer boosted their FY2022 earnings estimates for shares of SPX in a research report issued on Monday, December 20th. Oppenheimer analyst B. Blair now anticipates that the company will post earnings of $2.95 per share for the year, up from their previous forecast of $2.90. Oppenheimer also []

41246 (APO.V) (CVE:APO) Equities research analysts at Oppenheimer issued their Q3 2022 earnings per share estimates for shares of 41246 (APO.V) in a report issued on Tuesday, December 21st. Oppenheimer analyst L. Gershell forecasts that the company will post earnings of ($0.10) per share for the quarter. Oppenheimer also issued estimates for 41246 (APO.V)s []

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Investment analysts at Oppenheimer reduced their FY2021 earnings per share (EPS) estimates for Aldeyra Therapeutics in a report released on Monday, December 20th. Oppenheimer analyst J. Kim now anticipates that the biotechnology company will earn ($1.11) per share for the year, down from their previous forecast of ($1.09). Oppenheimer also []

HHM Wealth Advisors LLC acquired a new position in Vanguard Financials ETF (NYSEARCA:VFH) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,000 shares of the companys stock, valued at approximately $185,000. Several other institutional investors also recently bought and sold shares of VFH. Oppenheimer []

Amgen Inc. (NASDAQ:AMGN) Investment analysts at Oppenheimer boosted their FY2025 earnings per share estimates for Amgen in a research report issued to clients and investors on Monday, December 20th. Oppenheimer analyst J. Olson now forecasts that the medical research company will post earnings per share of $23.19 for the year, up from their prior []

Morgan Stanley (NYSE:MS) Equities research analysts at Oppenheimer lifted their Q1 2022 earnings estimates for Morgan Stanley in a report issued on Wednesday, December 22nd. Oppenheimer analyst C. Kotowski now anticipates that the financial services provider will post earnings of $1.95 per share for the quarter, up from their previous estimate of $1.93. Oppenheimer []

Littelfuse, Inc. (NASDAQ:LFUS) Equities research analysts at Oppenheimer cut their Q1 2022 EPS estimates for Littelfuse in a report released on Tuesday, December 21st. Oppenheimer analyst C. Glynn now anticipates that the technology company will earn $2.89 per share for the quarter, down from their prior estimate of $2.96. Oppenheimer also issued estimates for []

These four stocks are all trading below their book value, making it likely that their names are showing up on the value screens of large institutional investors. Since each one trades on the New York

Blade Air Mobility, Inc. (NASDAQ:BLDE) – Research analysts at Oppenheimer issued their FY2026 earnings estimates for Blade Air Mobility in a report released on Tuesday, December 21st. Oppenheimer analyst J. Helfstein forecasts that the company will post earnings per share of ($0.33) for the year. Oppenheimer currently has a “Outperform” rating and a $14.00 price […] The post Oppenheimer Weighs in on Blade Air Mobility, Inc.’s FY2026 Earnings (NASDAQ:BLDE) appeared first on ETF Daily News .

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Investment analysts at Oppenheimer cut their Q1 2022 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued on Monday, December 20th. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($1.07) per share for the quarter, down from their [] The post Q1 2022 Earnings Forecast for Global Blood Therapeutics, Inc. (NASDAQ:GBT) Issued By Oppenheimer appeared first on ETF Daily News .

Oppenheimer named cryptocurrency exchange Coinbase Global Inc (NASDAQ: COIN ) a top pick for 2022 Wednesday, citing the continued adoption of digital assets by retailers and institutions. "For institutional investors who are interested in getting exposure to digital assets, we believe COIN is well-positioned to benefit from it," Oppenheimer analyst Owen Lau said. Ritholtz Wealth Management CEO Josh Brown weighed in Wednesday afternoon on CNBC''s "Closing Bell." "This is the most obvious play in the stock market right now as far as a directional bet on whether or not there will be huge flows into crypto from institutions and wealth management next year," Brown said. "And I know there will Full story available on Benzinga.com

Oppenheimer is out with its 2022 picks and Coinbase (NASDAQ:COIN) has made the list. The analyst providing the coverage has set a $444 price target for the crypto exchange, a significant increase over its current per-share price that hovers around $252/share. Coinbase became a public Read More

Next year will be a stock-picker''s market, and these clean energy companies hold up well on a fundamental basis, according to Oppenheimer.